Measuring efficacy and safety of different inhaled corticosteroid preparations

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 6 II, 1998, Pages 879-886

  O'Byrne, Paul M ^a   Pedersen, Soren ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; STEROID; TRIAMCINOLONE ACETONIDE;

ADRENAL SUPPRESSION; ADULT; ASTHMA; CHILD; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; GROWTH DISORDER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; METERED DOSE INHALER; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0032433427     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(98)70322-7     Document Type: Article

References (54)

1. Morrow-Brown H. The introduction and early development of inhaled steroid therapy. In: Mygind N, Clark TJH, editors. Topical steroid treatment for asthma and rhinitis. London: Balliere Tindall; 1980. p. 66-76.
2. Pedersen S, O'Byrne PM. A comparison of the efficacy and safety of inhaled corticesteroids in asthma. Allergy 1997;52:1-34.
3. Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulized budesonide in preschool children with asthma. Arch Dis Child 1998. In press.
4. Brattsand R, Axelsson BI. New inhaled glucocorticosteroids. In: Barnes PJ, editor. New drugs for asthma. London: IBC Technical Services Ltd; 1992. p. 193-208.
5. Högger P, Rawert I, Rohdewald P. Dissolution, tissue binding and kinetics of receptor binding of inhaled glucocorticoids. Eur Respir J 1993;6:584s.
6. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157:1-53.
7. Miller-Larsson A, Mattson H, Ohlsson D, Hjertberg E, Tunek A, Dahlback M, et al. Prolonged release from the airway tissue of glucocorticosteroids budesonide and fluticasone propionate as compared to beclomethasone dipropionate and hydrocortisone. Am J Respir Crit Care Med 1994;149:A466.
8. Miller Larsson A, Hjertberg E, Mattsson H, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide results in a prolonged retention in airway tissue as compared to fluticasone propionate. Am J Respir Crit Care Med 1997;155:A353.
9. Miller Larsson A, Mattsson H, Hjertberg E, Dahlback M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998;26:623-30.
10. Thorsson L, Dahlström K, Edsbacker S, Källen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997;43:155-61.
11. Falcoz C, Mackie AE, Moss J, Horton J, Ventresca GP, Brown A, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler(r) and the Diskus(r) after repeat doses in healthy subjects and asthmatic patients. J Allergy Clin Immunol 1997;99:s505.
12. Hatter JG, Reddy WJ, Thorn GW. Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 1963;269:591-6.
13. Heuck C, Wolthers OD. Short term growth assessment of once versus twice daily inhaled budesonide in children with asthma. Eur Respir J 1995;8:470s.
14. Agertoft L, Wolthers O, Fuglsang G, Pedersen S. Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Pediatr Allergy Immunol 1993;4:152-6.
15. Pedersen S, Steffensen G, Ekman I, Tonnesson M, Borga O. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987;31:579-82.
16. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993;69:130-3.
17. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962;86:608-10.
18. Gruvstad E, Bengtsson B. A comparison of a new steroid, BUD, with other topical corticosteroids in the vasoconstrictor assay. Drugs Exp Clin Res 1980;6:385-90.
19. Johansson SA, Andersson K-E, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol 1982;22:523-9.
20. English AF, Neate MS, Quit DJ, Sareen M. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994;149:A212.
21. Andersson N, Klint S, Randwall G, Wiren JE. Equipotency of BUD and fluticasone propionate in the vasoconstrictor assay. Am J Respir Crit Care Med 1994;149:A467.
22. Johnson M. Anti-inflammatory properties of fluticasone propionate. Int Arch Allergy Immunol 1995;107:439-40.
23. Andersson M, Berglund R, Greiff L, Hammarlund A, Hedbys L, Malcus I, et al. A comparison of budesonide nasal dry powder with fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis. Rhinology 1995;33:18-22.
24. Stern MA, Dahl R, Nielsen LP, Pedersen B, Schrewelius C. A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms once daily and 256 micrograms once daily) and fluticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 1997;11:323-30.
25. Day J, Carrillo T, Schrewelius C, Jennings BH. A placebo-controlled study comparing aqueous suspensions of budesonide (BUD) and fluticasone propionate (FP) in patients with perennial allergic rhinitis. In: XVIth International Symposium on Infection and Allergy of the Nose; 1998. p. 142.
26. Dahl R, Lundback B, Malo J, Mazza JA, Nieminen MM, Saarelainen P, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1998;104:352-8.
27. Ellul-Micallef R, Johansson SA. Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide. Br J Clin Pharmacol 1983;15:419-22.
28. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995;95:29-33.
29. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998;101:457-63.
30. O'Byrne PM, Cuddy L, Taylor DW, Birch S, Morris J, Syrotiuk J. The clinical efficacy and cost benefit of inhaled corticosteroids as therapy in patients with mild asthma in primary care practice. Can Respir J 1996;3:169-75.
31. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF. Effect of 22 months of treatment with inhaled corticosteroids and/or β2-agonists on lung function, airway responsiveness and symptoms in patients with asthma. Am Rev Respir Dis 1992;146:547-54.
32. Condemi JJ, Chervinsky P, Goldstein MF, Ford LB, Berger WE, Ayars GH, et al. Fluticasone propionate powder administered through Diskhaler versus Triamcinolone acetonide aerosol administered through metered-dose inhaled in patients with persisting asthma. J Allergy Clin Immunol 1997;100:467-74.
33. Brown PH, Blundell G, Greening AP, Crompton GK. Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir Med 1991;85:511-6.
34. Wong J, Black P. Acute adrenal insufficiency associated with high dose inhaled steroids. Br Med J 1992;304:1415-6.
35. Toogood JH, Sorva R, Puolijoki H. Review of the effects of inhaled steroids therapy on bone. Int J Risk Saf Med 1994;5:1-14.
36. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared to theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92:64-77.
37. Doull I, Freezer N, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995;151:1715-9.
38. Pedersen S, Fuglsang G. Urinary cortisol excretion in children treated with high doses of inhaled corticosteroids: a comparison of budesonide and beclomethasone. Eur Respir J 1988;1:433-5.
39. Bisgaard H, Damkjaer Nilsen M, Andersen B. Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol 1988;80:213-7.
40. Grahnen A, Brundin RM, Ling-Andersson A, Lonnebro A, Eckernas SA. The systemic potency of fluticasone propionate from the Diskhaler vs budesonide from Turbuhaler. Am J Respir Crit Care Med 1996;153:A338.
41. Grove A, Allam C, McFarlane LC, McPhate G, Lipworth BJ. A comparison of the systemic bioactivity of inhaled budesonide and fiuticasone propionate in normal subjects. Br J Clin Pharmacol 1994;38:527-32.
42. Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systematic potency of inhaled fluticasone and budesonide. Eur Respir J 1996;9:1427-32.
43. Clark D, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996;51:262-6.
44. Clark D, Clark RA, Lipworth BJ. Comparative systemic bioactivity of inhaled budesonide and fluticasone propionate in asthmatic children. Br J Clin Pharmacol 1996;42:264.
45. Hoffman-Streb A, L'Allemand D, Niggemann B, Buttner P, Wahn U. Adrenocortical function in children with bronchial asthma under fluticasone treatment. Monatsschr Kinderheikd 1993;141:508-12.
46. Wilson AM, McFarlane LC, Lipworth BJ. Dose-response effect for adrenal supression with repeated twice daily fluticasone propionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med 1997;156:1274-7.
47. Boe J, Rosenhall L, Alton M, Carlsson LG, Carlsson U, Hermansson BA, et al. Comparison of dose-response effects of inhaled beclomethasone dipropionate and BUD in the management of asthma. Allergy 1989;44:349-55.
48. Brambilla C, Lacronique J, Allaert FA, Godard P, Duroux P. A 3 month comparative dose-response study with inhaled beclomethasone dipropionate and budesonide in the management of moderate to severe adult asthma. Drug Invest 1994;8:49-56.
49. Ayres JG, Bateman ED, Lundback B, Harris TA. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995;8:579-86.
50. Basran GS, Scott R, Campbell M, Knox A, Smith R, Vernon J, et al. A study to compare the efficacy of budesonide (pulmicort turbuhaler) and fluticasone propionate (flixotide Diskhaler) in the treatment of asthma. Thorax 1995;50:469P.
51. Agertoft L, Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol 1997;99:773-80.
52. Nicolaizik WH, Marchant JL, Preece MA, Warner JO. Endocrine and lung function in asthmatic children on inhaled corticosteroids. Am J Respir Crit Care Med 1994;150:624-8.
53. Fabbri L, Burge PS, Croonenborge L, Warlies F, Weeke B, Ciaccia A, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993;48:817-23.
54. Grahnen A, Brundin RM, Ling-Andersson A, Lonnebo A, Eckernas SA. The systemic potency of fluticasone propionate from Diskhaler vs budesonide from Turbuhaler. Am J Respir Crit Care Med 1996;153:A338.